Recent advances in non-small cell lung cancer targeted therapy; an update review
Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
decade, significant advancements in the diagnosis and treatment of lung cancer, particularly …
Targeting ALK rearrangements in NSCLC: current state of the art
L Peng, L Zhu, Y Sun, J Stebbing, G Selvaggi… - Frontiers in …, 2022 - frontiersin.org
Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
be effectively treated with a variety of ALK-targeted drugs. After the approval of the first …
[HTML][HTML] A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma
S Hernandez, E Conde, M Alonso… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
A narrative review of methods for the identification of ALK fusions in patients with non-small
cell lung carcinoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
cell lung carcinoma - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …
Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling
T Wang, L Wei, Q Lu, Y Shao, S You, JC Yin… - NPJ Precision …, 2022 - nature.com
Recurrent fusions of receptor tyrosine kinases (RTKs) are often driving events in
tumorigenesis that carry important diagnostic value and are potentially targetable by the …
tumorigenesis that carry important diagnostic value and are potentially targetable by the …
Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusions
B Li, H Qu, J Zhang, W Pan, M Liu, X Yan… - NPJ precision …, 2021 - nature.com
Kinase fusions represent an important type of somatic alterations that promote oncogenesis
and serve as diagnostic markers in lung cancer. We aimed to identify the landscape of …
and serve as diagnostic markers in lung cancer. We aimed to identify the landscape of …
Sex-Hormone-Binding Globulin Gene Polymorphisms and Breast Cancer Risk in Caucasian Women of Russia
I Ponomarenko, K Pasenov, M Churnosova… - International Journal of …, 2024 - mdpi.com
In our work, the associations of GWAS (genome-wide associative studies) impact for sex-
hormone-binding globulin (SHBG)-level SNPs with the risk of breast cancer (BC) in the …
hormone-binding globulin (SHBG)-level SNPs with the risk of breast cancer (BC) in the …
Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
Y Wang, S Shen, P Hu, D Geng, R Zheng… - Cancer Medicine, 2022 - Wiley Online Library
Background Anaplastic lymphoma kinase (ALK) fusion is a prognostic indicator for patients
with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real …
with non‐small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitors (TKIs). The real …
Genetic correlation of crizotinib efficacy and resistance in ALK-rearranged non-small-cell lung cancer
C Liu, C Liu, J Liao, JC Yin, X Wu, X Zhao, S Sun… - Lung Cancer, 2022 - Elsevier
Objectives Crizotinib remains one of the most commonly used targeted therapies for ALK
fusion-positive patients. However, the mutational profiles and mechanisms of resistance to …
fusion-positive patients. However, the mutational profiles and mechanisms of resistance to …
Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis
Y Sun, S Qin, S Wang, J Pang, Q Ou… - The Journal of …, 2024 - Wiley Online Library
Pulmonary spindle cell carcinoma (PSCC) is a rare and aggressive non‐small cell lung
cancer (NSCLC) subtype with a dismal prognosis. The molecular characteristics of PSCC …
cancer (NSCLC) subtype with a dismal prognosis. The molecular characteristics of PSCC …
Predicting differences in treatment response and survival time of lung adenocarcinoma patients based on a prognostic risk model of glycolysis-related genes
R Zhao, D Ding, Y Ding, R Han, X Wang… - Frontiers in Genetics, 2022 - frontiersin.org
Background: Multiple factors influence the survival of patients with lung adenocarcinoma
(LUAD). Specifically, the therapeutic outcomes of treatments and the probability of …
(LUAD). Specifically, the therapeutic outcomes of treatments and the probability of …